Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J A de Jonge

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 3, 2006
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?M J A de Jonge, J Verweij
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
The use of oral cytotoxic and cytostatic drugs in cancer treatmentA Sparreboom, M J A de Jonge, J Verweij
Critical Reviews in Oncology/Hematology|April 17, 2009
Aurora kinase inhibitorsJ J E M Kitzen, M J A de Jonge, J Verweij
European Journal of Cancer (Oxford, England : 1990)|March 12, 2003
Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validationD Moneta, C Geroni, O Valota, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development GroupC J A Punt, M J A de Jonge, S Monfardini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Influence of the cisplatin hydration schedule on topotecan pharmacokineticsH Gelderblom, W J Loos, A Sparreboom, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2008
Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I studyW K de Jong, M J A de Jonge, A H D van der Leest, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2006
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumorsA Felici, W J Loos, J Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2007
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumoursL Scott, O Soepenberg, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2011
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumoursM J A de Jonge, H Dumez, J J E M Kitzen, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|June 3, 2006
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?M J A de Jonge, J Verweij
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
The use of oral cytotoxic and cytostatic drugs in cancer treatmentA Sparreboom, M J A de Jonge, J Verweij
Critical Reviews in Oncology/Hematology|April 17, 2009
Aurora kinase inhibitorsJ J E M Kitzen, M J A de Jonge, J Verweij
European Journal of Cancer (Oxford, England : 1990)|March 12, 2003
Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validationD Moneta, C Geroni, O Valota, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development GroupC J A Punt, M J A de Jonge, S Monfardini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Influence of the cisplatin hydration schedule on topotecan pharmacokineticsH Gelderblom, W J Loos, A Sparreboom, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2008
Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I studyW K de Jong, M J A de Jonge, A H D van der Leest, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2006
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumorsA Felici, W J Loos, J Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2007
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumoursL Scott, O Soepenberg, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2011
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumoursM J A de Jonge, H Dumez, J J E M Kitzen, et al.
Pageof 3